Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript
02:14am, Friday, 09'th Jan 2026
Krystal Biotech, Inc. (KRYS) Discusses Positive Interim Results and Next Steps for Cystic Fibrosis Program KB407 Transcript
KRYS Stock Surges 57% in a Year: More Upside Potential in 2026?
10:45am, Thursday, 08'th Jan 2026
Shares of Krystal Biotech soar 57% in a year as strong Vyjuvek uptake and steady pipeline progress continue to push the stock higher.
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference
08:00am, Wednesday, 26'th Nov 2025
PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conferen
Commonwealth of Pennsylvania Public School Empls Retrmt SYS Purchases 472 Shares of Krystal Biotech, Inc. $KRYS
04:09am, Monday, 24'th Nov 2025
Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 7.8% during the second quarter, according to its most recent 13F filing with
Campbell & CO Investment Adviser LLC Invests $274,000 in Krystal Biotech, Inc. $KRYS
03:51am, Tuesday, 18'th Nov 2025
Campbell and CO Investment Adviser LLC bought a new stake in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) in the second quarter, according to the company in its most recent Form 13F filing with the
Krystal Biotech: Vyjuvek Gene Therapy Well Positioned For Growth
09:00am, Sunday, 16'th Nov 2025
Krystal Biotech is rated a buy after a strong Vyjuvek launch, but the current valuation reflects premium margins and aggressive global expansion projections. Vyjuvek's US sales growth has plateaued, b
Aviva PLC Increases Stock Position in Krystal Biotech, Inc. $KRYS
04:00am, Friday, 14'th Nov 2025
Aviva PLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ: KRYS) by 9.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange C
AlphaQuest LLC Trims Stock Holdings in Krystal Biotech, Inc. $KRYS
04:13am, Thursday, 06'th Nov 2025
AlphaQuest LLC trimmed its position in Krystal Biotech, Inc. (NASDAQ: KRYS) by 65.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange
Krystal's Q3: Platform Designation Adds Pipeline Leverage As Vyjuvek Scales (Rating Upgrade)
05:17pm, Monday, 03'rd Nov 2025
Krystal Biotech (KRYS) reported strong Q3 results, with Vyjuvek delivering $97.8M revenue, 96% gross margin, and a new at-home use label. KRYS's disciplined operating expenses and robust cash position
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript
11:46am, Monday, 03'rd Nov 2025
Krystal Biotech, Inc. ( KRYS ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Stephane Paquette - Vice President of Corporate Development Krish Krishnan - Founder, Chairman, P
Krystal Biotech (KRYS) Projected to Post Quarterly Earnings on Monday
02:00am, Saturday, 01'st Nov 2025
Krystal Biotech (NASDAQ: KRYS - Get Free Report) is expected to be releasing its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Krystal Biotech to post earnings of $1
Krystal Biotech, Inc. (KRYS) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Monday, 27'th Oct 2025
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
11:21am, Tuesday, 30'th Sep 2025
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
01:55pm, Tuesday, 16'th Sep 2025
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin
01:39pm, Monday, 15'th Sep 2025
The U.S. Food and Drug Administration (FDA) on Monday approved Krystal Biotech, Inc.'s KRYS label update for Vyjuvek (beremagene geperpavec-svdt).
